BACKGROUND: Limited information is known about the clinical significance of cancers diagnosed upon repeat biopsy for the indication of atypical small acinar proliferation (ASAP). With increasing concern regarding overdiagnosis and overtreatment of prostate cancer, and the reported rise in infectious complications related to prostate biopsy, we examined the outcomes of patients rebiopsied for a diagnosis of ASAP. METHODS: Clinical, pathologic and outcomes data of patients diagnosed with ASAP on prostate biopsy at our institutions between 2000 and 2010 were abstracted through chart review. Statistical analyses included Fisher's exact and the two-sample Wilcoxon rank sum tests. Logistic regression evaluated risk factors for the probability of cancer following a diagnosis of ASAP. RESULTS: A total of 349 patients met the inclusion criteria with median follow-up of 4.4 years. Median age was 65.3 years with a median PSA of 5.3 ng ml -1 . Of men diagnosed with ASAP, 250/349 (71.6%) had a repeat biopsy within 1 year with 94/246 (38.2%) demonstrating prostate cancer; only 26/245 (10.6%) had ⩾ Gleason 7 disease. Of men diagnosed with ASAP, 284/349 (81.4%) underwent biopsy at some time during follow-up. Prostate cancer was diagnosed in 132/279 (47.3%) of these men, 48/278 (17.3%) with ⩾ Gleason 7 disease. Multivariate analyses suggested that older age, no previous biopsy and PSA density were predictive of cancer on repeat biopsy within 1 year from ASAP. Univariate analysis revealed PSA density was associated with the presence of ⩾ Gleason 7 disease at 1 year and any time after a diagnosis of ASAP. CONCLUSIONS: The overall rate of intermediate-and high-grade prostate cancer found on repeat biopsy for ASAP is low. Further investigation into ways to further risk stratify these men may be warranted. However, until such tests become available, repeat biopsy of men diagnosed with ASAP remains prudent.
INTRODUCTION
Prostate cancer remains a significant public health concern. It is estimated that over 238 000 men were diagnosed with prostate cancer in 2013. 1 Recent studies have shown that although PSA screening can reduce the risk of death from prostate cancer bỹ 20%, it does so at a significant risk of overdiagnosis. 2, 3 In addition, there has been a noted increase in the prevalence of fluoroquinolone-resistant bacteria resulting in an increase in infectious complications following transrectal ultrasound (TRUS)guided prostate biopsy. 4, 5 Atypical small acinar proliferation (ASAP) is a pathologic finding seen on prostate biopsy that is closely associated with the coexistence of prostate cancer. 6, 7 Previous studies have shown a significant rate of prostate cancer found upon rebiopsy of men with an initial diagnosis of ASAP with an average cancer detection rate of 40%. 8 For this reason the National Comprehensive Cancer Network recommends that men with a diagnosis of ASAP undergo repeat biopsy within 3 months with increased sampling of the area(s) with ASAP. However, little is known about the pathologic outcomes of the cancers detected in men for this indication. Increasing concerns about overdiagnosis and possible overtreatment of some men with prostate cancer, as well as the recent increase in infectious complications from TRUS-guided biopsies has called into question the aggressive diagnosis of men who may harbor low-risk disease. We examined the pathologic outcomes of men at our institutions who underwent repeat prostate biopsy for a diagnosis of ASAP to determine the rate of ⩾ Gleason 7 disease in these men.
MATERIALS AND METHODS
Institutional review board approval was granted for this study by both participating institutions. We retrospectively examined the electronic medical record at the Minneapolis Veterans Affairs hospital and at the University of Minnesota between the years 2000 and 2010 and identified cases where a diagnosis of ASAP was reported on the prostate biopsy pathology report. Men were excluded from this analysis if they had a prior diagnosis of prostate cancer or if prostate cancer was diagnosed simultaneously with ASAP. Our search yielded 290 men from the Veterans Affairs and 59 men from University of Minnesota for a total of 349 men included in this study. Clinical and pathologic data were abstracted from the medical record. Index and repeat biopsies were performed according to the standard of the institutions at the time of the biopsy without a standardized protocol. The numbers and rates of subsequent cancers following the ASAP diagnosis are summarized by frequencies and percentages. Univariate analysis includes Fisher's exact test for categorical factors and the two-sample Wilcoxon rank sum test for quantitative variables. Logistic regression was used to evaluate possible risk factors for the probability of cancer following ASAP. A P-value o0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
Median age of the men was 65.3 years and the median PSA at the time of ASAP diagnosis was 5.3 ng ml -1 . Abnormal digital rectal exams were noted in 28.6% (89/311) of the men. The majority of men, 76.4% (259/339), had not undergone any prior biopsies before their diagnosis of ASAP. Follow-up data were available for a median of 4.4 years (0-12.3 years) following the diagnosis of ASAP. Table 1 provides a complete list of demographic data.
The standard of care for men with a diagnosis of ASAP is to undergo repeat biopsy. We determined that 71.6% (250/349) of our patients underwent a repeat biopsy within 1 year from their ASAP diagnosis. It was assumed that biopsies occurring within this time frame were performed primarily owing to the finding of ASAP, and not for other reasons such as further rise in PSA or change in digital rectal exam. With further follow-up, a total of 81.4% (284/349) of our cohort were documented to have undergone at least one repeat biopsy for any cause at any time during the follow-up period. Thus, most men were adherent to the recommendation to undergo repeat biopsy following a diagnosis of ASAP.
Repeat prostate biopsy within 1 year from original ASAP diagnosis was documented in 250 men. Four men were excluded for incomplete data. Consistent with previous studies, we found that of the men receiving at least one repeat biopsy within the first year following the diagnosis of ASAP, cancer was found in 38.2% (94/246). Further, of the men who subsequently received a repeat biopsy at any time following their diagnosis of ASAP, cancer was found 47.3% (132/279) of the time (five men were excluded due to incomplete data). We then determined the prevalence of significant cancer identified on repeat biopsy in men diagnosed with ASAP as defined by the presence of Gleason 7 or higher on the biopsy. Of men who received a repeat biopsy within the first year following their ASAP diagnosis, Gleason sum 7 or higher was seen in 28% (26/94) of the men with positive repeat biopsies, and thus in only 10.6% (26/245) of the cohort of men who underwent repeat biopsy within the year from ASAP diagnosis (one patient was excluded for incomplete data). Further, we noted ⩾ Gleason 7 disease in 36.6% (48/132) of men with a positive biopsy whose biopsy occurred at any time after ASAP diagnosis, resulting in a diagnosis of Gleason 7 or higher cancer in only 17.3% (48/278) of the group of men who ever received a repeat biopsy following a diagnosis of ASAP (one patient excluded due to incomplete data). We next sought to identify characteristics that might be predictive of the finding of cancer on repeat biopsy following a diagnosis of ASAP. Univariate analysis identified family history, the number of negative biopsies and PSA density to be associated with the risk of a cancer diagnosis at any time following the initial ASAP diagnosis, whereas PSA density and the number of prior negative biopsies were associated with the risk of a cancer diagnosis at 1 year and at any time following a diagnosis of ASAP (Table 2) . When these factors were included in a multivariate model along with standard clinicopathologic features, age was associated with an increased risk of cancer diagnosis within the first year of 23% for every 5-year increase in age, and PSA density was associated with an increase in the risk of a cancer diagnosis within the first year of 36% for every 0.1-unit increase. Having had a previous negative biopsy before a diagnosis of ASAP was associated with a decreased risk of a cancer diagnosis in the first year of 64% (Table 3) . Family history was associated with a nearly twofold increased risk of a cancer diagnosis at any time, whereas PSA density and age remained significant risk factors as well, and previous negative biopsy before a diagnosis of ASAP remained protective (Table 4 ).
We further evaluated predictors of finding ⩾ Gleason 7 disease. Univariate analysis considering similar clinicopathologic features as above revealed PSA density as the only feature associated with the presence of ⩾ Gleason 7 cancer in our study. PSA density was associated with ⩾ Gleason 7 disease both at 1 year and anytime following a diagnosis of ASAP (Table 5 ). Multivariate models to predict finding ⩾ Gleason 7 disease failed to identify any significant covariates.
DISCUSSION
There is growing concern that widespread PSA testing has led to possible overdiagnosis and overtreatment of some men with prostate cancer. In addition, infectious complications of prostate biopsy are increasing. 4, 5 The United States Preventive Services Task Force has come out against PSA screening for all men in this country 9 and the American Urological Association has published recent guidelines that narrow the scope and intensity of recommended PSA screening in response to these growing concerns. 10 It is important to recognize, however, that PSA screening does decrease the risk of death from prostate cancer in appropriately selected men. 3 Thus, a one-size-fits-all approach to managing patients at risk for prostate cancer no longer seems appropriate. Increased rates of infections following TRUS biopsies has complicated the evaluation of men with elevated PSAs as the majority of men undergoing biopsy for this indication will be negative or diagnosed with a low-risk cancer. Further, even patients who choose observation for low-risk cancer may face increased risks of infectious complications from repeat biopsies as part of surveillance protocols. 11 As many men undergoing a prostate biopsy for an elevated PSA results in the diagnosis of insignificant cancer, we hypothesized that men diagnosed with prostate cancer after an initial diagnosis of ASAP may be even more likely to harbor low-grade disease and thus may not warrant immediate definitive therapy if diagnosed. Further, it remains unclear whether men with a low likelihood of harboring higherrisk disease warrant an aggressive strategy to diagnose all cancer immediately. Thus, although we advocate for identification and treatment of aggressive cancers, the risk/benefit calculation for diagnosing men with low-or very low-risk disease is less clear, particularly for those men with limited life expectancy. We therefore sought to determine the rate of Gleason 7 or higher disease upon repeat biopsy in men with a diagnosis of ASAP that could have implications for the recommendation of repeat biopsy in all such men.
Our results are consistent with previous reports in terms of the overall rate of cancer found on biopsy following a diagnosis of ASAP. However, our study is one of only a few studies to determine the clinical significance of the cancers diagnosed in this manner. Iczkowski et al. 6 reported an overall cancer detection rate of 42% (125/295) and a 29% (36/125) rate of Gleason 7 or above disease on repeat biopsy among those with a positive biopsy after a diagnosis of ASAP, and a 12% (36/295) rate of these cancers in their overall cohort of 295 men. Hoedemaeker et al. 12 reported finding cancer in 15/39 (39%) men undergoing repeat biopsy for 'borderline' lesions. Three of the 15 (20%) men had Gleason 7 or higher. Of note, the repeat biopsies of these men were performed by taking four cores from the region of the prostate where the borderline lesion was documented, and no other biopsies from other parts of the prostate. Chan et al. 13 reported cancer upon repeat biopsy in 45/92 (48.9%) men with 20% having Gleason 7 or higher, or~10% of their overall cohort. Chen et al. 14 published on the findings at prostatectomy from men undergoing radical prostatectomy for cancer found after an initial diagnosis of ASAP. They noted that 88% (149/169) of men found to have cancer on repeat biopsy after ASAP had Gleason scores of 5-6 on repeat biopsy as well as lower tumor volumes compared with men diagnosed with cancer without a prior diagnosis of ASAP. At radical prostatectomy, 75% (126/169) of men were found to have Gleason 6 disease, whereas 25% were found to have Gleason 7 or higher (one patient with Gleason 8). Interestingly, a diagnosis of ASAP was associated with a lower Gleason score and pathological stage (higher likelihood of organ-confined status) compared with men whose cancer was diagnosed without a prior diagnosis of ASAP. It is noteworthy that our study and those cited above including that of Iczkowski reported very similar rates of cancer and Gleason 7 and above disease despite the different eras in which the studies were conducted and the wide range in the number and distribution of cores obtained on both original and follow-up biopsies. The results of our study and those noted above suggest that overall, there is a relatively low rate of Gleason sum 7 or higher disease diagnosed in men on repeat biopsy obtained within the first year following a diagnosis of ASAP with~90% of these men having either negative biopsies or Gleason scores ⩽ 6. Table 3 . The significant predictors from the factors in Table 2 for the probability of cancer during the first year following ASAP using multivariate logistic regression (N = 233) This rate increased somewhat in our study in men who subsequently underwent repeat biopsy after the first year. It is presumed that many of these men likely underwent repeat biopsy for an additional indication such as further increase in PSA or a change in digital rectal exam, and thus may represent men with a higher likelihood of harboring more aggressive disease and more likely to benefit from definitive treatment. Despite the similar rates of disease observed over time, a different response to these observations may be worth consideration now when interpreted in the current context of concern of overdiagnosis and increased risk of infections from TRUS biopsies. In previous eras when there was an emphasis on diagnosing all prostate cancer aggressively, repeat biopsy of all patients with ASAP made sense owing to the significant rate of coexistence of ASAP and prostate cancer. However, in the current climate of concern of overdiagnosis, additional study to determine which patients with ASAP are at higher risk of harboring clinically significant disease may be warranted as our data and that of others suggests that the vast majority of men undergoing repeat biopsy for this indication are unlikely to be diagnosed with cancers of Gleason score 7 or above. To date, no previous studies have been able to identify clinical features of patients or pathologic features of ASAP biopsies predictive of cancer on repeat biopsy. Although PSA density was associated with a risk of cancer on repeat biopsy in our cohort, and of finding ⩾ Gleason 7 disease, unfortunately we were unable to identify a specific PSA density cutoff that allowed for adequate discrimination of men with and without cancer or between those with o and ⩾ Gleason 7 disease on repeat biopsy (data not shown). It is possible that with further study, such cutoffs may be possible to identify. Age and the presence or absence of a previous negative biopsy before the ASAP diagnosis may also be helpful in predicting the presence or absence of cancer.
Previous reports as well as the current study report the results of biopsies (initial and repeat) based on TRUS guidance. It is unclear what impact the use of magnetic resonance imaging (MRI)-guided or MRI/TRUS fusion biopsy strategies may have on the outcomes of repeat biopsies. Similarly, it is unclear what the significance is of the finding of ASAP on a MRI-guided biopsy if no other abnormality suspicious for cancer is noted on imaging; this would decrease the likelihood of the coexistence of a large highgrade lesion. MRI-targeted biopsies have been shown to improve detection of high-grade cancer and result in detection of higher volumes of cancer per core compared with TRUS-guided biopsies. 15, 16 In the future, it is possible that integration of multiparametric MRI (with subsequent MRI-guided biopsies) may help identify men diagnosed with ASAP most likely to benefit from diagnosis and subsequent treatment of cancer. It is likely that an optimal algorithm will include imaging with other known clinicopathologic features including age, family history and PSA density among others.
We recognize several limitations to this study including its retrospective nature that could have resulted in selection bias among men who underwent repeat biopsy as well as resulting in missing data for some men. The relatively small sample size is another limitation, although this is among the largest reported studies on the outcomes of patients with a diagnosis of ASAP and to our knowledge, the largest to report outcomes of Gleason scores in this population. In addition, we did not have central review of the pathologic slides. As this study involves cases over a large period of time and from two different institutions, it is possible that the criteria used to define a diagnosis of ASAP was somewhat variable. However, the consistency in findings between our study and previously published studies noted above argues against there being significant bias due to era of the study. Finally, a standard biopsy scheme was not employed, which could have affected cancer detection rates as well.
CONCLUSION
Men diagnosed with ASAP who undergo repeat biopsy within the first year have a low likelihood of being diagnosed with ⩾ Gleason 7 prostate cancer. The risk of a cancer diagnosis increases in men who were biopsied beyond a year after a diagnosis of ASAP likely due to additional indications for biopsy and may represent men with a higher likelihood of benefit from definitive management. Therefore, further study to identify men most likely to benefit from immediate repeat biopsy after a diagnosis of ASAP may be warranted. However, until such tests are available, repeat biopsy of these men remains prudent.
